scholarly journals Beta‐2‐Glycoprotein‐I Deficiency Could Precipitate an Antiphospholipid Syndrome‐like Prothrombotic Situation in Patients With Coronavirus Disease 2019

2021 ◽  
Author(s):  
Manuel Serrano ◽  
Gerard Espinosa ◽  
Antonio Lalueza ◽  
Luz Yadira Bravo‐Gallego ◽  
Raquel Diaz‐Simón ◽  
...  
Keyword(s):  
Antiphospholipid Syndrome ◽  
Glycoprotein I ◽  
Beta 2

Antiphospholipid syndrome – an update

VASA ◽  
2018 ◽  
Vol 47 (6) ◽  
pp. 451-464 ◽  
Author(s):  
Birgit Linnemann
Keyword(s):  
Antiphospholipid Syndrome ◽  
Lupus Erythematosus ◽  
Clinical Symptoms ◽  
Heart Valve Disease ◽  
Small Vessels ◽  
Glycoprotein I ◽  
Neurologic Disorders ◽  
Cardiolipin Antibodies ◽  
Obstetric Aps ◽  
Beta 2

Abstract. Antiphospholipid syndrome (APS) is an autoantibody-mediated acquired thrombophilia. It is characterized by the presence of antiphospholipid antibodies (APL) that are directed against phospholipid-binding plasma proteins, such as beta-2-glycoprotein I (b2GPI). Its main manifestations are recurrent vascular thromboses (so-called “thrombotic APS”) and pregnancy complications (“obstetric APS”). According to the current consensus criteria, a persistently positive functional lupus anticoagulant (LA) assay and/or the presence of anti-b2GPI and/or anti-cardiolipin antibodies, together with clinical symptoms, is mandatory for the diagnosis of APS. Other clinical features, such as thrombocytopenia, Coombs-positive haemolytic anaemia, heart valve disease, renal microangiopathy and neurologic disorders are also common in APL-positive patients. APS can be associated with other autoimmune disorders, such as systemic lupus erythematosus. In rare cases, catastrophic APS (CAPS) occurs, with the development of excessive thrombosis at multiple sites, usually affecting small vessels and leading to multi-organ dysfunction and organ failure. Treatment usually comprises antithrombotic therapy using antiplatelet and anticoagulant agents. However, there is no consensus concerning the intensity or duration of therapy. Despite apparently adequate anticoagulation, the risk of recurrent thrombosis remains high. For patients with CAPS, a combined therapeutic approach that includes anticoagulation, glucocorticoids, plasma exchange and/or intravenous immunoglobulin seems to be the best treatment option. Keywords: Antiphospholipid syndrome, lupus anticoagulants, anti-cardiolipin, anti-beta-2-glycoprotein I, vascular thrombosis, pregnancy complication

Anti-beta 2-glycoprotein I antibodies: a marker of antiphospholipid syndrome?

Lupus ◽  
1995 ◽  
Vol 4 (2) ◽  
pp. 122-130 ◽  
Author(s):  
Genesio Balestrieri ◽  
Angela Tincani ◽  
Laura Spatola ◽  
Flavio Allegri ◽  
Enrica Prati ◽  
...  
Keyword(s):  
Antiphospholipid Syndrome ◽  
Glycoprotein I ◽  
Beta 2

Cross-reactivity between annexin A2 and Beta-2-glycoprotein I in animal models of antiphospholipid syndrome

2016 ◽  
Vol 65 (1) ◽  
pp. 355-362 ◽  
Author(s):  
R. Weiss ◽  
A. Bitton ◽  
L. Nahary ◽  
M. T. Arango ◽  
I. Benhar ◽  
...  
Keyword(s):  
Animal Models ◽  
Antiphospholipid Syndrome ◽  
Cross Reactivity ◽  
Annexin A2 ◽  
Glycoprotein I ◽  
Beta 2

Immunization with Anticardiolipin Cofactor (Beta-2-Glycoprotein I) Induces Experimental Antiphospholipid Syndrome in Naive Mice

1994 ◽  
Vol 7 (4) ◽  
pp. 441-455 ◽  
Author(s):  
Miri Blank ◽  
David Faden ◽  
Angela Tincani ◽  
Juri Kopolovic ◽  
Iris Goldberg ◽  
...  
Keyword(s):  
Antiphospholipid Syndrome ◽  
Glycoprotein I ◽  
Beta 2

scholarly journals Anti-beta 2-glycoprotein I antibodies: a useful marker for the antiphospholipid syndrome

Rheumatology ◽  
1997 ◽  
Vol 36 (1) ◽  
pp. 113-116 ◽  
Author(s):  
M. Teixido ◽  
J. Font ◽  
J. C. Reverter ◽  
R. Cervera ◽  
D. Tassies ◽  
...  
Keyword(s):  
Antiphospholipid Syndrome ◽  
Glycoprotein I ◽  
Beta 2

The Significance of Antibodies against Domain I of Beta-2 Glycoprotein I in Antiphospholipid Syndrome

2017 ◽  
Vol 44 (05) ◽  
pp. 458-465 ◽  
Author(s):  
Walid Chayouâ ◽  
Hilde Kelchtermans ◽  
Bas Laat
Keyword(s):  
Risk Stratification ◽  
Antiphospholipid Syndrome ◽  
Clinical Manifestations ◽  
Detection Methods ◽  
Clinical Value ◽  
Pregnancy Morbidity ◽  
Glycoprotein I ◽  
Patients At Risk ◽  
Beta 2 ◽  
Domain I

AbstractThe antiphospholipid syndrome (APS) is characterized by vascular thrombosis and/or pregnancy morbidity with the persistent presence of antiphospholipid antibodies (aPLs). Progress is being made in understanding the pathogenesis of the syndrome, but difficulties persist in the identification of patients at risk for thrombosis and/or pregnancy morbidity. Beta-2 glycoprotein I (β2GPI), a plasma protein consisting of five sushi domains, is thought to be the main antigenic target of aPLs. Antibodies recognizing domain I of β2GPI are predominantly present in patients with an elevated risk of thrombosis, whereas antidomain IV/V antibodies are found in nonthrombotic autoimmune diseases. Indeed, domain I antibodies proved to be pathogenic in multiple studies. Retrospective studies have provided evidence for an added clinical value of antidomain I antibodies in the risk stratification of patients with APS. Still, wide ranges of odds ratio exist between studies, probably due to differences in the study and control population, and detection methods used. Despite the proven pathogenicity of antidomain I antibodies and their correlations with clinical manifestations of APS, heterogeneity of the current studies has prohibited their acceptance in the official diagnostic criteria. Well-designed large longitudinal prospective studies with available and new, preferentially functional, assays for the risk stratification of patients with APS are required.

Sign in / Sign up

Export Citation Format

Share Document